The biotech award in 2020 for being in the right place at the right time could well go to AdAlta. The long-awaited Phase 1 trial commences in the middle of the COVID-19 pandemic. While IPF is not currently a household name, it soon could be given the alarming incidence of IPF infection following the SARS coronavirus outbreak in 2003.
What will happen in the aftermath of COVID-19 if the devastating impact of lung scarring increases in the general population beyond historical levels of significance?
@Few Pennies makes the point that why might big pharma want to do a deal so soon? well maybe because of covid 19 they might be predicting that over the next few years the addressable market could easily go many times bigger than just $3.5 billion...
And this is in a market area, due to the unmet need and limited therapeutic options, where early deals are not unusual. How is the Phase 1 trial going? Of course, the first cohorts are in healthy patients but going on the announcement of 14 December 2020, the critical aspect of expected receptor occupancy is above expectations. In short, early results indicate that AD-214 hangs around for longer than anticipated which potentially means longer dosing intervals. Potential partners could well be delighted particularly as we head into Part B of the trial where AD-214 will be administered in a patient population.
1AD Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)